Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy La Jolla Pharmaceutical stock

Learn how to easily invest in La Jolla Pharmaceutical stock.

La Jolla Pharmaceutical Co is a biotechnology business based in the US. La Jolla Pharmaceutical shares (LJPC) are listed on the NASDAQ and all prices are listed in US Dollars. La Jolla Pharmaceutical employs 61 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in La Jolla Pharmaceutical

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – LJPC – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

La Jolla Pharmaceutical stock price (NASDAQ: LJPC)

Use our graph to track the performance of LJPC stocks over time.

La Jolla Pharmaceutical shares at a glance

Information last updated 2022-07-02.
Latest market close$3.12
52-week range$3.10 - $5.08
50-day moving average $3.76
200-day moving average $4.13
Wall St. target price$4.00
PE ratio 19.5
Dividend yield $0 (0%)
Earnings per share (TTM) $0.16

Buy La Jolla Pharmaceutical shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy La Jolla Pharmaceutical stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

La Jolla Pharmaceutical price performance over time

Historical closes compared with the close of $3.12 from 2022-07-01

1 week (2022-06-24) -9.83%
1 month (2022-06-02) -18.96%
3 months (2022-03-29) N/A
6 months (2021-12-29) -32.90%
1 year (2021-07-02) -27.61%
2 years (2020-07-02) -29.25%
3 years (2019-07-02) 9.51
5 years (2017-06-30) 29.77

Is La Jolla Pharmaceutical stock undervalued or overvalued?

Valuing La Jolla Pharmaceutical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of La Jolla Pharmaceutical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

La Jolla Pharmaceutical's P/E ratio

La Jolla Pharmaceutical's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 20x. In other words, La Jolla Pharmaceutical shares trade at around 20x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

La Jolla Pharmaceutical's EBITDA

La Jolla Pharmaceutical's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.1 million.

The EBITDA is a measure of a La Jolla Pharmaceutical's overall financial performance and is widely used to measure a its profitability.

La Jolla Pharmaceutical financials

Revenue TTM $52 million
Operating margin TTM 4.68%
Gross profit TTM $63.1 million
Return on assets TTM 1.64%
Return on equity TTM 0%
Profit margin 10.08%
Book value $-0.61
Market capitalisation $79.7 million

TTM: trailing 12 months

La Jolla Pharmaceutical share dividends

We're not expecting La Jolla Pharmaceutical to pay a dividend over the next 12 months.

Have La Jolla Pharmaceutical's shares ever split?

La Jolla Pharmaceutical's shares were split on a 1:50 basis on 13 January 2014. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your La Jolla Pharmaceutical shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for La Jolla Pharmaceutical shares which in turn could have impacted La Jolla Pharmaceutical's share price.

La Jolla Pharmaceutical share price volatility

Over the last 12 months, La Jolla Pharmaceutical's shares have ranged in value from as little as $3.1 up to $5.08. A popular way to gauge a stock's volatility is its "beta".

LJPC.US volatility(beta: 1.96)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while La Jolla Pharmaceutical's is 1.9578. This would suggest that La Jolla Pharmaceutical's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

La Jolla Pharmaceutical overview

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts. .

Frequently asked questions

What percentage of La Jolla Pharmaceutical is owned by insiders or institutions?
Currently 1.418% of La Jolla Pharmaceutical shares are held by insiders and 68.804% by institutions.
How many people work for La Jolla Pharmaceutical?
Latest data suggests 61 work at La Jolla Pharmaceutical.
When does the fiscal year end for La Jolla Pharmaceutical?
La Jolla Pharmaceutical's fiscal year ends in December.
Where is La Jolla Pharmaceutical based?
La Jolla Pharmaceutical's address is: 201 Jones Road, Waltham, MA, United States, 02451
What is La Jolla Pharmaceutical's ISIN number?
La Jolla Pharmaceutical's international securities identification number is: US5034596040
What is La Jolla Pharmaceutical's CUSIP number?
La Jolla Pharmaceutical's Committee on Uniform Securities Identification Procedures number is: 503459505

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site